FDA approves first generic loteprednol eyedrop
Akorn, Inc. announced the approval of their generic steroid eyedrop, loteprednol etabonate ophthalmic suspension 0.5%. Source: AAO
- Posted on: Apr 23 2019
- Leave a response
Akorn, Inc. announced the approval of their generic steroid eyedrop, loteprednol etabonate ophthalmic suspension 0.5%. Source: AAO
The extent and progression of hydroxychloroquine (HCQ) retinopathy can be monitored using en face OCT, according to this retrospective study. Source: AAO
This randomized controlled trial, also known as the Zhongshan Angle Closure Prevention (ZAP) trial, evaluated the efficacy of prophylactic laser peripheral iridotomy (LPI) in bilateral angle-closure suspects. Source: AAO
This week, a gene therapy for Leber hereditary optic neuropathy provides a sustained vision boost, the Supreme Court blocks Allergan’s bid to shield Restasis from generic competition and a partnership between the Georgia O’Keeffe museum and EnChroma could help colorblind art enthusiasts experience a new level of vibrancy. Source: AAO
The authors comprehensively summarize existing evidence for methods used to reduce injection pain, specifically in the context of periocular procedures. Source: AAO
This retrospective study describes the authors’ experience using intravitreal chemotherapy to treat non-vitreous disease that is refractory to intra-arterial chemotherapy. Source: AAO
This Ophthalmic Technology Assessment evaluated the ability of orthokeratology (ortho-K) treatment to reduce myopic progression compared with standard refractive correction (spectacles or daytime contact lenses). Source: AAO
This multicenter retrospective study compared the rate of endophthalmitis between prefilled syringes and conventional preparation of ranibizumab. Source: AAO
Investigators document a case of retinal necrosis with counting fingers vision in a patient who received an injection of methylprednisolone acetate (Depo-Medrol) during complicated cataract surgery. Source: AAO
This study describes a new approach using data from spectral-domain (SD) OCT to train a deep-learning (DL) algorithm for quantifying glaucomatous structural damage. Source: AAO
Tel: 518-580-0553
Get Directions »
Tel: 518-580-0553
Get Directions »
Tel: +1 (518) 580-0553
Get Directions »